Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AIM-HI Accelerator Fund is a U.S.-based 501(c)(3) nonprofit and venture-philanthropy accelerator focused on advancing early-stage oncology and patient-empowering health-tech companies. Created in 2019 by the National Foundation for Cancer Research, the organization aims to bridge the translational funding gap between academic discovery and clinical/commercial development. Rather than developing its own therapeutic pipeline, AIM-HI provides seed funding, venture competitions, coaching, business development support, and network access to startup companies. The fund reports support for roughly 30 startups since inception and emphasizes an evergreen impact-investing model in which returns are reinvested into future cancer innovation. Its activities center on enabling new cancer therapies, diagnostics, and related health technologies to move from bench to bedside.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AIM-HI Accelerator Fund.